Torsade de pointes probably induced by sparfloxacin

Journal of Association of Physicians of India

Volumn 50, Issue 8, 2002, Pages 1077-1078

  Kakar, A ^a   Byotra, S P ^a  

^a SIR GANGA RAM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; SPARFLOXACIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEMALE; HUMAN; LUNG TUBERCULOSIS; TORSADE DES POINTES;

ADULT; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; TORSADES DE POINTES; TUBERCULOSIS, PULMONARY;

EID: 0036691959     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Yap YG, Camm J. Risk of torsodes de pointes with non-cardiac drugs. Doctors need to aware that many drugs can cause QT prolagation. BMJ 2000;320:1158-9.
2. Cohen MA, Yoder SL, Talbot GH. sparfloxacin worldwide in vitro literature: isolated data available through 1994. Diagn Microbiol Infect Dis 1996;25:53-64.
3. Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother 1996;37(Suppl A): 161-7.
4. Goa KL, Bryson HM, Marknam A, Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997;53:700-25.
5. Adamantidis MM, Dumotier BM, Caron JF, Bordet R. Sparfloxacin but not levofloxacin or ofloxacin prolonges cardiac repolarization in rabbit purkinje fibres. Fundam Clin Pharmacol 1998;12:70-6.
6. Dupont H, Timsit JF, Souweine B, et al. Torsades de pointes probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis 1996;15:350-1.